Abdullah ALGIN, Abuzer ÖZKAN, Serdar ÖZDEMIR, Hatice Şeyma AKÇA, Ibrahim ALTUNOK

Hızlı İlerleyen SARS-CoV-2 Enfeksiyonu: Olgu Sunumu

Aralık 2019’da SARS’a neden olan yeni tip bir coronavirüs bildirildi ve SARS-CoV-2 olarak adlandırıldı. Dünya çapında 31.000.000’den fazla vaka doğrulandı ve 962.000’den fazla hasta bu viral enfeksiyondan öldü. Kliniğimize üç gündür ateş ve öksürük şikayetleri ile başvuran 31 yaşında erkek hasta başvurdu. Özgeçmişinde hastalık öyküsü yoktu. Bilgisayarlı tomografide hafif pnömoni izlendi. Hidroksi klorokin tedavisi ile taburcu edildi. Dört gün sonra nefes darlığı ile tekrar kliniğimize başvurdu. Pnömoni kısa sürede hızla ilerledi. Tedaviye Tazocin, favipiravir ve azitromisin eklendi. Medikal tedavi ve yüzüstü pozisyonlama ile destekleyici oksijene rağmen hasta desatüre oldu ve vefat etti. Sonuç olarak; COVID-19 için bilinen mortalite prediktörleri olmayan hastalar da ölümle sonuçlanabilmektedir. COVID-19 hastalarının klinik seyirleri yakından takip edilmelidir.

Rapidly Progressed SARS-CoV-2 Infection: A Case Report

In December 2019 new type of coronavirus which did causes severe acute respiratory syndrome was reported and named as SARS-CoV-2. Globally, over 31 000 000 cases were confirmed, and over 962 000 patients have died from this viral infection. A 31-year-old male patient was admitted to our clinic with fever and cough for three days. He was healthy, he did not have any specific medical history. At first admission, computed tomography showed mild pneumonia. He was discharged with treatment of hydroxychloroquine. He was admitted again to our clinics four days later with a compliant of dyspnea. Pneumonia progressed rapidly in a short period. Piperacillin-tazobactam combination, favipiravir and azithromycin were added to therapy. Although supplementary oxygen and prone positioning added to medical therapy, the patient was desaturated and died. As a conclusion; patient without known predictors of mortality for COVID-19, can result in death. Patients with COVID-19 should be followed closely for clinical course.

PDF

___

1. Şener A. COVİD-19 (SARS Cov-2) tedavisi. J Biotechnol and Strategic Health Res 2020;1:97-104.
2. Satıcı B, Gocet Tekin E, Deniz ME, Satıcı SA. Adaptation of the fear of COVID-19 scale: Its association with psychological distress and life satisfaction in Turkey. Int J Ment Health Addict 2020;8:1-9.
3. Hatipoğlu N. The “new” problem of humanity: New coronavirus (2019-nCoV/COVID-19) disease. Med J Bakirkoy 2020;16(1):1- 8.
4. COVID-19 situation update worldwide, as of 20 September 2020. [Internet] [cited. Sep 20, 2020]. https://www.ecdc.europa. eu/en/geographical-distribution-2019-ncov-cases
5. COVID-19 Algoritmalar [Internet] [cited. May 15, 2020]. Available from: https://covid19bilgi.saglik.gov.tr/tr/algoritmalar
6. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020;395(10223):507-513.
7. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020;395(10229):1054-1062.
8. Sandalcı B, Uyaroğlu OA, Güven GS. COVID-19’da kronik hastalıkların rolü, önemi ve öneriler. Flora 2020;25(5);1-7
9. Velavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory markers. Int J Infect Dis 2020;93:304-307.
10. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;46:846-848.